Mili Arora, M.D.

Mili Arora, M.D.

Specialties

Hematology/Oncology

Cancer

Benign and Malignant Hematology

Oncology

Breast Cancer

Department

Internal Medicine

Title

  • Assistant Professor (HSCP)

Reviews

To see if Mili Arora is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

4501 X Street, 2nd Floor
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

Additional Phone Numbers

Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Arora's clinical interests are in breast cancer, benign and malignant hematology.

Division

Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.D., George Washington University, Washington DC 2009

B.S., Virginia Commonwealth University, Richmond VA 2004

Residency

Internal Medicine, Tufts Medical Center, Boston MA 2009-2012

Fellowships

Hematology/Oncology, UC Davis Medical Center, Sacramento CA 2012-2015

Board Certifications

American Board of Internal Medicine,

Professional Memberships

American College of Physicians (ACP)

American Society of Clinical Oncology

American Society of Hematology (ASH)

Southwest Oncology Group (SWOG)

Honors and Awards

Placer Breast Cancer Foundation award for research/trial work, 2019

Christine and Helen Landgraf Memorial Research Award recipient, 2019

Chief Fellow, UC Davis, 2014, 2015

Select Recent Publications

For a comprehensive list of Dr. Arora's publications, please click here (opens new window).

Sauder C, Li Q, Othieno A, Cruz D, Arora M, Bold R, Meyers F, Keegan T. Characteristics and outcomes for secondary breast cancer in children, adolescent and young adult cancer survivors treated with radiation. Cancer Epidemiology Biomarkers & Prevention. 2020 Sept. doi:10.1158/1055-9965.EPI-20-0260.

Poh C, Arora M, Ghuman S, Tuscano J. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. Acta Haematologica. 2020 Apr;1-5. doi:10.1159/000506918. PMID:32348994.

Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):e291-294. doi:10.1002/ajh.25605. Epub 2019 Aug 20. PMID:31379016.

Bateni SB, Davidson AJ, Arora M, Daly ME, Stewart SL, Bold RJ, Canter RJ, Sauder CAM. Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis. Ann Surg Oncol. 2019 Jul;26(7):2144-2153. doi:10.1245/s10434-019-07159-4. Epub 2019 Feb 13. PMID:30761438. PMCID:PMC6545266.

Schwab E, Chen JA, Huynh JC, Ji J, Arora M, Cho M, Kim EJ. Rational Strategies for Combining Bcl-2 Inhibition with Targeted Drugs for Anti-Tumor Synergy. J Cancer Treatment Diagn. 2019;3(4):7-13.

Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016 Aug;7(4):209–221. Published online 2016 Jul 1. doi:10.1177/2040620716652861. PMID:27493711.

Chew H, Arora M, Verman R. Breast Cancer. Ed. Robert M. McCarron, Glen L. Xiong, and Henry A. Nasarallah, (ed). Preventive Medical Care in Psychiatry, First ed. 2014;19:275-288.

Arora M, Wun T. Adverse impact of venous thromboembolism on patients with cancer. Semin Thromb Hemost. 2014 Apr;40(3):313-8. doi:10.1055/s-0034-1370769. Epub 2014 Mar 5. PMID:24599435.

Arora M, Cossor F. Diagnosis of extracavitary primary effusion lymphoma by urine cytology. Blood. 2012;119(12):2707. doi:10.1182/blood-2011-04-319103.

Kimchi-Sarfaty C, Arora M, Marple CH, Kimchi A, Gurwitz D, Gottessman M. Ethnicity-Related Polymorphisms and Haplotypes in the Human ABCB1 gene. Pharmacogenomics. 2007 Jan;8(1):29-29. doi:10.2217/14622416.8.1.29. PMID:17187507.